The Avanzar study could read out shortly.
ApexOnco Front Page
Recent articles
Satri-cel is filed for gastric cancer approval in China.
Reports of Arc-10's failure are greatly exaggerated, the company argues.
An ASH abstract reveals no delayed neurotoxicity, but three deaths, with anito-cel.
Failed trials of vibostolimab and domvanalimab will be unveiled at SITC late-breakers.
After beating "historical" Xtandi masofaniten fails to beat actual Xtandi.
October's US approvals included Scemblix, Vyloy and Itovebi, while Lumakras was delayed.
The group goes after a KRAS-related target on which Boehringer recently gave up.